Indie brand built a three-arm multi-peptide serum from the expanded range in 10 weeks
A US indie beauty brand wanted a single hero serum that told a multi-peptide story — firmness, expression lines, and repair — drawing one active from each mechanistic lane rather than three from the same family. Coordinated sourcing and carrier-compatibility scoping took the build from brief to first commercial fill in 10 weeks.
Published May 28, 2026 · Anonymized customer story
Brief → first commercial fill
~10 weeks
Carrier-validation passes
1 (all three actives, shared base)
Claim arms
3 · signal + neurotransmitter + carrier
Mechanistic lanes covered
3 (no redundant actives)
Challenge
The brand's founder had been advised by a marketing agency to pack 'as many peptides as possible' into a relaunch serum, and the first draft INCI deck carried four matrikines that all told the same firmness story — one claim arm, quadrupled, at a cost the small-batch model could not carry. The Head of Product wanted to rebuild the serum as a genuine multi-peptide formula: one signal peptide for firmness, one neurotransmitter peptide for the expression-line appearance, and one carrier peptide for the repair narrative, each mapping to a distinct, documentable claim. They needed a single supplier that could source all three at cosmetic grade, flag whether they would co-formulate, and keep the total active load realistic against the retail price point — inside a 10-week relaunch window.
Approach
Pepoderma's brand partnerships team mapped the brief to three mechanistic lanes and quoted one active per arm from the expanded range: a Matrixyl-family matrikine (signal), Acetyl Octapeptide-3 / SNAP-8 (neurotransmitter), and Copper Tripeptide-1 / GHK-Cu (carrier). The compatibility review flagged the single decision that shaped the whole formula — the GHK-Cu copper coordination — and the brand's contract manufacturer built the base chelator-free and copper-clean around it, with the lipidated matrikine pre-dispersed in a co-solvent slurry and the water-soluble actives added cool and late. A 100 g sample set across all three actives went to the manufacturer for a single carrier-validation pass rather than three separate ones, each lot carrying INCI, CAS, and an allergen and trace-impurity sheet. A one-page order-of-addition and use-level card sized each arm against the brand's stated price point.
Outcome
The sample set landed at the contract manufacturer inside the first fortnight, and a single carrier-validation pass cleared all three actives in the shared base. First commercial fill shipped around the 10-week mark, on the relaunch calendar. The reworked serum carried a three-arm claim — each phrase mapping to a named, documented INCI active — that the brand's regulatory reviewer signed off without flagging, and the total peptide load came in materially below the original four-matrikine draft because the arms were complementary rather than redundant.
“We were about to pay for four peptides that all said the same thing. Rebuilding it as one signal, one expression-line, and one copper peptide gave us a serum that actually reads as multi-peptide on pack — and the copper-coordination flag up front saved our manufacturer a stability headache none of us saw coming.”